NMN vs NR: Choosing The Right Precursor
CELYFE Research
The debate between NMN (Nicotinamide Mononucleotide) and NR (Nicotinamide Riboside) as the optimal NAD+ precursor has been central to the longevity supplementation space. Both molecules serve as precursors to NAD+, but they enter the biosynthetic pathway at different points.
NR is converted to NMN by the enzyme NRK (Nicotinamide Riboside Kinase), and NMN is then converted to NAD+ by NMNAT enzymes. This means NMN is one step closer to NAD+ in the biosynthetic pathway, potentially offering a more direct route to NAD+ elevation.
A significant development came with the discovery of the Slc12a8 transporter by Imai et al. (2019), which demonstrated that NMN can be directly transported into cells in the gut, suggesting a specific cellular uptake mechanism that NR does not share.
In terms of stability, NR has historically been considered more stable in oral supplement form. However, advances in NMN formulation and delivery methods - including subcutaneous administration - have addressed many stability concerns.
CELYFE takes a different route entirely: rather than relying on a precursor and the enzymatic conversion steps above, the NAD+ Precision Pen delivers NAD+ directly via subcutaneous administration - bypassing both the gut and the conversion pathway to maximize bioavailability. This reflects our commitment to optimizing the NAD+ restoration pathway.
Regardless of precursor choice, the evidence supports that restoring NAD+ levels through supplementation may support healthy cellular function. The optimal choice may ultimately depend on individual factors including age, health status, and administration preferences.
*These products are food supplements and are not intended to diagnose, treat, cure, or prevent any disease. This product has not been evaluated by the European Food Safety Authority (EFSA) or the U.S. Food and Drug Administration (FDA). Content is for informational purposes only and should not be considered medical advice.